Total Payments
$185,291
2023 Payments
$21,494
Companies
13
Transactions
92
Medicare Patients
605
Medicare Billing
$129,593
Payment Breakdown by Category
Consulting$71,027 (38.3%)
Other$61,787 (33.3%)
Research$44,425 (24.0%)
Travel$5,956 (3.2%)
Food & Beverage$2,097 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $71,027 | 28 | 38.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $61,788 | 22 | 33.3% |
| Unspecified | $44,425 | 2 | 24.0% |
| Travel and Lodging | $5,956 | 14 | 3.2% |
| Food and Beverage | $2,097 | 26 | 1.1% |
Payments by Type
General
$140,866
90 transactions
Research
$44,425
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $56,199 | 44 | $0 (2023) |
| Foundation Medicine, Inc. | $54,440 | 17 | $0 (2023) |
| Aveo Pharmaceuticals, Inc. | $44,425 | 2 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $13,495 | 11 | $0 (2018) |
| Genentech USA, Inc. | $3,758 | 5 | $0 (2023) |
| AstraZeneca UK Limited | $3,425 | 2 | $0 (2020) |
| Incyte Corporation | $2,792 | 2 | $0 (2021) |
| Sirtex Medical Inc | $2,635 | 2 | $0 (2022) |
| ARRAY BIOPHARMA INC | $2,361 | 1 | $0 (2021) |
| Exelixis Inc. | $1,709 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $21,494 | 8 | Foundation Medicine, Inc. ($18,428) |
| 2022 | $66,073 | 12 | Aveo Pharmaceuticals, Inc. ($44,425) |
| 2021 | $23,693 | 9 | Foundation Medicine, Inc. ($17,000) |
| 2020 | $6,505 | 4 | AstraZeneca UK Limited ($3,425) |
| 2019 | $6,203 | 5 | Ipsen Biopharmaceuticals, Inc ($6,191) |
| 2018 | $28,341 | 24 | Ipsen Biopharmaceuticals, Inc ($19,816) |
| 2017 | $32,982 | 30 | Ipsen Biopharmaceuticals, Inc ($22,616) |
All Payment Transactions
92 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/03/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $11,115.00 | General |
| Category: Oncology | ||||||
| 09/26/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 05/17/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 03/14/2023 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $870.00 | General |
| Category: Oncology | ||||||
| 02/14/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,632.50 | General |
| Category: Oncology | ||||||
| 01/20/2023 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,925.00 | General |
| Category: Oncology | ||||||
| 01/20/2023 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $160.99 | General |
| Category: Oncology | ||||||
| 01/20/2023 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $110.78 | General |
| 12/23/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,632.50 | General |
| Category: Oncology | ||||||
| 12/17/2022 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Interventional Oncology | ||||||
| 12/13/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $3,217.50 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,632.50 | General |
| Category: Oncology | ||||||
| 11/23/2022 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $135.25 | General |
| Category: Interventional Oncology | ||||||
| 11/08/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,462.50 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,047.50 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,755.00 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,755.00 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2022 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | — | Cash or cash equivalent | $31,034.90 | Research |
| Study: A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma • Category: Oncology | ||||||
| 05/26/2022 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | — | Cash or cash equivalent | $13,390.00 | Research |
| Study: A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma • Category: Oncology | ||||||
| 03/29/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $3,510.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2021 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2021 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,767.50 | General |
| 10/20/2021 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $24.49 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | Aveo Pharmaceuticals, Inc. | $44,425 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 51 | 81 | $43,434 | $9,181 |
| 2021 | 8 | 287 | 594 | $174,595 | $69,596 |
| 2020 | 7 | 267 | 494 | $148,457 | $50,816 |
Total Patients
605
Total Services
1,169
Medicare Billing
$129,593
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 16 | 45 | $31,050 | $7,184 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 36 | $12,384 | $1,997 | 16.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 48 | 236 | $37,760 | $37,760 | 100.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 103 | 188 | $64,672 | $14,662 | 22.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 43 | 69 | $32,016 | $7,737 | 24.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $12,616 | $2,827 | 22.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $12,715 | $2,490 | 19.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 24 | $8,064 | $1,856 | 23.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 18 | 19 | $3,040 | $1,531 | 50.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 16 | $3,712 | $732.41 | 19.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 45 | 182 | $29,120 | $28,880 | 99.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 83 | 154 | $52,976 | $9,040 | 17.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 39 | 39 | $20,787 | $3,999 | 19.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 32 | 38 | $17,632 | $2,895 | 16.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 17 | $11,118 | $2,567 | 23.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 38 | 45 | $10,440 | $1,881 | 18.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 19 | $6,384 | $1,553 | 24.3% |
About Dr. Shaalan Beg, MD
Dr. Shaalan Beg, MD is a Internal Medicine healthcare provider based in Boise, Idaho. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1508077298.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shaalan Beg, MD has received a total of $185,291 in payments from pharmaceutical and medical device companies, with $21,494 received in 2023. These payments were reported across 92 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($71,027).
As a Medicare-enrolled provider, Beg has provided services to 605 Medicare beneficiaries, totaling 1,169 services with total Medicare billing of $129,593. Data is available for 3 years (2020–2022), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Boise, ID
- Active Since 05/24/2007
- Last Updated 12/12/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508077298
Products in Payments
- FOUNDATIONONE CDX (Device) $54,440
- FOTIVDA (Drug) $44,425
- Onivyde (Drug) $25,951
- OPDIVO (Biological) $13,495
- Somatuline Depot 120mg-.5ml (Drug) $12,022
- ONIVYDE (Drug) $10,811
- Somatuline Depot (Drug) $7,415
- Avastin (Biological) $3,648
- SIR-Spheres Microspheres (Device) $2,635
- BRAFTOVI (Drug) $2,361
- Cabometyx (Drug) $1,709
- Stivarga (Drug) $20.43
- BEVYXXA (Drug) $19.00
- KEYTRUDA (Biological) $11.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boise
Theodore Roosevelt, M.d, M.D
Internal Medicine — Payments: $224,566
Internal Medicine $224,566
Ashley Evans, Md, MD
Internal Medicine — Payments: $95,647
Internal Medicine $95,647
Huiling Qi, M.d, M.D
Internal Medicine — Payments: $38,813
Internal Medicine $38,813
Dr. Adam Grimaldi, M.d, M.D
Internal Medicine — Payments: $23,011
Internal Medicine $23,011
Dr. Carolyn Bridges, M.d, M.D
Internal Medicine — Payments: $19,716
Internal Medicine $19,716
Kendra Coonse, M.d, M.D
Internal Medicine — Payments: $16,388
Internal Medicine $16,388